# Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension

> **NCT05920005** · PHASE3 · COMPLETED · sponsor: **Hospital Israelita Albert Einstein** · enrollment: 702 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** candesartan cilexetil + chlorthalidone + amlodipine
- **DRUG:** Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)

## Key facts

- **NCT ID:** NCT05920005
- **Lead sponsor:** Hospital Israelita Albert Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-22
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-05-01
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920005, "Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05920005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*